The Business Research Company’s Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
LONDON, GREATER LONDON, UNITED ARAB EMIRATES, August 19, 2026 /EINPresswire.com/ — The market for non-alcoholic steatohepatitis (NASH) biomarkers is experiencing rapid expansion as advancements in medical research and diagnostics continue to evolve. This growing sector plays a crucial role in improving the detection and management of liver-related diseases, especially with rising health concerns linked to metabolic conditions. Let’s explore the current market size, the factors driving growth, regional leadership, and emerging trends shaping this important healthcare niche.
Market Size and Growth Outlook for the Non-Alcoholic Steatohepatitis Biomarkers Market
The non-alcoholic steatohepatitis biomarkers market has witnessed significant growth over recent years. It is projected to increase from $1.68 billion in 2025 to $2.08 billion in 2026, representing a compound annual growth rate (CAGR) of 23.2%. This historical growth is attributed to the rising prevalence of metabolic disorders, including obesity and type 2 diabetes, expansion in liver disease research, availability of advanced diagnostic tests, and heightened pharmaceutical focus on developing therapies targeting NASH.
Download a free sample of the non-alcoholic steatohepatitis biomarkers market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR
Looking ahead, the market is expected to surge even further, reaching an estimated $4.6 billion by 2030 with a CAGR of 22.0%. Factors driving this forecast include increased investments in precision hepatology, growing demand for non-invasive diagnostic solutions, expansion of clinical trials centered on biomarkers, the rising adoption of personalized medicine approaches, and a stronger emphasis on managing diseases at early stages. Key trends during this period will likely feature the development of non-invasive diagnostic biomarkers, wider use of serum-based NASH biomarkers, integration of artificial intelligence in biomarker analysis, growth in companion diagnostics within drug development, and intensified focus on early disease detection.
Understanding Non-Alcoholic Steatohepatitis and the Role of Biomarkers
Non-alcoholic steatohepatitis (NASH) is a liver condition characterized by inflammation and damage caused by fat accumulation in liver cells. Biomarkers in this context serve as measurable indicators that help evaluate the extent of liver damage and the severity of the disease. These biomarkers provide critical information about ongoing disease processes, biological health status, or responses to treatment, thereby aiding in diagnosis and ongoing monitoring. Without proper detection and management, NASH can lead to serious complications such as cirrhosis and liver failure.
View the full non-alcoholic steatohepatitis biomarkers market report:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR
Primary Factors Fueling Growth in the Non-Alcoholic Steatohepatitis Biomarkers Market
A major factor propelling the growth of the NASH biomarkers market is the increasing prevalence of liver cancer. Liver cancer involves the development of malignant tumors within the liver and can originate there (primary cancer) or spread from other parts of the body (secondary or metastatic cancer). NASH biomarkers are instrumental in the early detection of liver cancer, tracking disease progression, evaluating treatment effectiveness, and providing prognostic insights. They also help reduce reliance on invasive diagnostic procedures.
Supporting this growth, in July 2025, the UK-based cancer journal ecancer medical science reported projections indicating that new liver cancer cases worldwide are expected to nearly double—from 870,000 in 2022 to 1.52 million by 2050. This increase is largely driven by population growth and aging demographics, with the sharpest rises forecasted in Africa. Liver cancer-related deaths are also predicted to climb from 760,000 in 2022 to 1.37 million by 2050. These statistics highlight the critical role of NASH biomarkers in responding to the expanding liver cancer burden.
Regional Leadership and Market Growth Trends in Non-Alcoholic Steatohepatitis Biomarkers
In 2025, North America held the position as the largest regional market for NASH biomarkers. However, the Asia-Pacific region is expected to witness the fastest growth during the forecast period. Other key regions covered in the market analysis include South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. The rapid development in Asia-Pacific is driven by increasing healthcare investments, rising incidences of metabolic disorders, and expanding access to advanced diagnostic technologies.
What’s included in our 2026 market reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
